1. Cazaubon, M., Benigni, J. P., Steinbruch, M., Jabbour, V., & Gouhier­-Kodas, C. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence. Vascular Health and Risk Management. 2021;17:591.

2. Shami, S. K., Sarin, S., & Scurr, J. H. Chronic venous insufficiency disease. International Journal of Angiology. 1997;6(01):30-48.

3. Labropoulos, N.How does chronic venous disease progress from the first symptoms to the advanced stages? A review. Advances in therapy. 2019;36(1):13-19.

4. Rabe, E., Guex, J. J., Morrison, N., Ramelet, A. A., Schuller-Petro­vic, S., Scuderi, A., et al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013;28(6):308-319.

5. Zheng, Y., Zhang, R., Shi, W., Li, L., Liu, H., Chen, Z., et al. Metabo­lism and pharmacological activities of the natural health-benefiting compound diosmin. Food & function. 2020;11(10): 8472-8492.

6. Garner, R. C., Garner, J. V., Gregory, S., Whattam, M., Calam, A., & Leong, D. Comparison of the Absorption of Micronized (Daflon 500® mg) and Nonmicronized 14C-diosmin Tablets After Oral Ad­ministration to Healthy Volunteers by Accelerator Mass Spectro­metry and Liquid Scintillation Counting. Journal of pharmaceutical sciences. 2002;91(1):32-40.

7. Struckmann, J. Pharmacological and Pharmacoclinical Properties of Daflon 500 mg (R). Drugs of Today. 1995;31:29-36.

8. Dholakiya, S. L., & Benzeroual, K. E. Protective effect of diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF-. expres­sion. Toxicology in Vitro. (2011;25(5):1039-1044.

9. Ahmed, S., Mundhe, N., Borgohain, M., Chowdhury, L., Kwatra, M., Bolshette, N., et al. Diosmin modulates the NF-kB signal trans­duction pathways and downregulation of various oxidative stress markers in alloxan-induced diabetic nephropathy. Inflammation. 2016;39(5): 1783-1797.

10. Jain, D., Bansal, M. K., Dalvi, R., Upganlawar, A., & Somani, R. Protective effect of diosmin against diabetic neuropathy in expe­rimental rats. Journal of integrative medicine. 2014;12(1):35-41.

11. Binuclara, J., Raghunandakumar, S., Asokkumar, S., Naveenkumar, C., Premkumar, T., & Devaki, T. Antifibrotic effect of diosmin against DMN-induced liver fibrosis in rats: a biochemical analysis. Int. J. Res. Pharm. Nanosci 2013;2(3):283-292.

12. Juteau, N., Bakri, F., Pomies, J. P., Foulon, C., Rigaudy, P., Pillion, G., et al. The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction. International Angiology: a Journal of the In­ternational Union of Angiology. 1995;14(3 Suppl 1):8-13.

13. Amato, C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. Angiology. 1994;45.

14. Guilhou, J. J., Dereure, O., Marzin, L., Ouvry, P., Zuccarelli, F., De-bure, C., et al. Efficacy of Daflon 500 mg in venous leg ulcer he­aling: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology. 1997;48(1):77-85.

15. Shelygin, Y., Krivokapic, Z., Frolov, S. A., Kostarev, I. V., Astashov, V. L., Vasiliev, S. V., et al. Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. Current Medical Research and Opinion. 2016;32(11):1821-1826.

16. Ramelet, A. A., Boisseau, M. R., Allegra, C., Nicolaides, A., Ja­eger, K., Carpentier, P., et al. Forconi. Veno-active drugs in the management of chronic venous disease. An international con­sensus statement: current medical position, prospective views, and final resolution. Clinical hemorheology and microcirculation. 2005;33(4):309-319.